Vaxcyte (PCVX) Receivables - Net (2021)

Vaxcyte (PCVX) has reported Receivables - Net for 4 consecutive years, with $298000.0 the latest figure, recorded in Q3 2024.

• In Q3 2024, Receivables - Net fell 84.2% year-over-year to $298000.0; the TTM figure through Sep 2024 stood at $298000.0 (down 84.2% YoY), while the FY2023 annual figure was $9000.0, down 99.13% from the prior year.
• Receivables - Net eased to $298000.0 in Q3 2024 per PCVX's latest filing, from $394000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $5.0 million in Q3 2021 and bottomed at $9000.0 in Q4 2023.
• Historically, Receivables - Net has averaged $1.2 million across 4 years, with a median of $394000.0 in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Net tumbled 99.13% — and 2024, when it sank 84.2%.
• Vaxcyte's Receivables - Net stood at $5.0 million in 2021, then slumped by 79.42% to $1.0 million in 2022, then sank by 99.13% to $9000.0 in 2023, then soared by 3211.11% to $298000.0 in 2024.
• Business Quant data shows PCVX's Receivables - Net at $298000.0 in Q3 2024, $394000.0 in Q2 2024, and $127000.0 in Q1 2024.